- Home
- Publications
- Publication Search
- Publication Details
Title
Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 20, Pages 12067
Publisher
MDPI AG
Online
2022-10-11
DOI
10.3390/ijms232012067
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis
- (2022) Linjun Shi et al. MOLECULAR THERAPY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immunogenicity of CAR T cells in cancer therapy
- (2021) Dimitrios L. Wagner et al. Nature Reviews Clinical Oncology
- Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
- (2021) Usha Menon et al. LANCET
- T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review
- (2021) Jessica W. Y. Wu et al. Frontiers in Immunology
- Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
- (2021) Shixue Chen et al. Frontiers in Oncology
- Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
- (2021) Bradley J Monk et al. LANCET ONCOLOGY
- Tumor immune microenvironment lncRNAs
- (2021) Eun-Gyeong Park et al. BRIEFINGS IN BIOINFORMATICS
- Mismatch Repair Deficiency in Ovarian Carcinoma
- (2020) Susanna Leskela et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors
- (2020) Curtis David Chin et al. MODERN PATHOLOGY
- Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
- (2020) Fulvio Borella et al. Diagnostics
- Gated Resonance Energy Transfer (gRET) Controlled by Programmed Death Protein Ligand 1
- (2020) Hubert Grel et al. Nanomaterials
- MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment
- (2020) Nannan Song et al. Frontiers in Cell and Developmental Biology
- Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
- (2020) Fabienne Maibach et al. Frontiers in Immunology
- A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming
- (2020) Lorena Incorvaia et al. Cancers
- Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
- (2019) Hyun Lee et al. MOLECULES
- LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195
- (2019) Qing-Ming Wang et al. LIFE SCIENCES
- Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway
- (2019) Chunrong Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
- (2019) Lin Wang Journal of Ovarian Research
- Ovarian Cancer Immunotherapy: Turning up the Heat
- (2019) Eleonora Ghisoni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer
- (2019) Sarah Nersesian et al. Frontiers in Immunology
- The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
- (2019) Weiting Qin et al. Frontiers in Immunology
- The Role of Long Non-coding RNAs in Immunotherapy Resistance
- (2019) Yuwen Zhou et al. Frontiers in Oncology
- Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
- (2019) Antonio González‐Martín et al. CANCER
- Long non-coding RNA LSINCT5 promotes ovarian cancer cell proliferation, migration and invasion by disrupting the CXCL12/CXCR4 signalling axis
- (2018) Xingtao Long et al. Oncology Letters
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- NKX2-1-AS1 negatively regulates CD274/PD-L1, cell-cell interaction genes, and limits human lung carcinoma cell migration
- (2018) Hasmeena Kathuria et al. Scientific Reports
- Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
- (2018) Curtis McCloskey et al. Cancers
- Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
- (2018) Maureen L. Drakes et al. Cancers
- Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200
- (2018) MICHAEL I. KOUKOURAKIS et al. ANTICANCER RESEARCH
- Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment
- (2018) A. Pawłowska et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials
- (2018) Emily Hinchcliff et al. GYNECOLOGIC ONCOLOGY
- Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
- (2017) Xinxin Zhu et al. Journal of Gynecologic Oncology
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- The Dualistic Model of Ovarian Carcinogenesis
- (2016) Robert J. Kurman et al. AMERICAN JOURNAL OF PATHOLOGY
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
- (2016) John R. Webb et al. GYNECOLOGIC ONCOLOGY
- Tumor infiltrating lymphocytes in ovarian cancer
- (2015) Phillip P Santoiemma et al. CANCER BIOLOGY & THERAPY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- microRNA-4717 differentially interacts with its polymorphic target in the PD1 3’ untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases
- (2015) Guoyu Zhang et al. Oncotarget
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
- (2015) Francesca De Felice et al. Journal of Immunology Research
- LncRNA: A link between RNA and cancer
- (2014) Guodong Yang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Programmed death-1 pathway in cancer and autoimmunity
- (2014) Ariel Pedoeem et al. CLINICAL IMMUNOLOGY
- MicroRNA-33a inhibits lung cancer cell proliferation and invasion by regulating the expression of β-catenin
- (2014) CHANGLIANG ZHU et al. Molecular Medicine Reports
- Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer
- (2013) Christian J. Maine et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cell cycle regulation by long non-coding RNAs
- (2013) Masatoshi Kitagawa et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
- (2013) K. Abiko et al. CLINICAL CANCER RESEARCH
- Long non-coding RNAs: new players in cell differentiation and development
- (2013) Alessandro Fatica et al. NATURE REVIEWS GENETICS
- Precursors and pathogenesis of ovarian carcinoma
- (2013) D. Lim et al. PATHOLOGY
- B7 family checkpoint regulators in immune regulation and disease
- (2013) Sabrina Ceeraz et al. TRENDS IN IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel molecular mechanism in human genetic disease
- (2012) Daphne S. Cabianca et al. RNA Biology
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
- (2011) Wei-Ting Hwang et al. GYNECOLOGIC ONCOLOGY
- Breast and Ovarian Cancers
- (2011) Atsuko Yoneda et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- Pathogenesis of Ovarian Cancer
- (2009) Robert J. Kurman et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Ovarian Cancer
- (2008) Kathleen R. Cho et al. Annual Review of Pathology-Mechanisms of Disease
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now